By Alistair Smout and Maggie Fick

LONDON (Reuters) – Britain’s biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.

The decision on the investment, which had been set to create 1,000 jobs, means none of AstraZeneca’s planned new funding – originally announced in March 2024 – is currently proceeding.

In January, the company scrapped plans to invest 450 million pounds in its vaccine manufacturing plant in northern England, citing a cut in British government support.

U.S. drugmaker Merck & Co this week blamed the UK’s challenging business environment as it abandoned a new research centre in London.

Asked about speculation over its pharmaceutical in

See Full Page